7:45 AM - 8:45 AM

Registration & Breakfast

8:45 AM - 9:00 AM

Chairman’s Opening Remarks

Smart Pharma: Key Trends That Will Enable The Reshaping of Drug Discovery and Development

This opening session will set the stage for the discussions that will take place over the course of the Summit and identify the key trends that are taking hold in biopharma and reshaping drug discovery and clinical development. Themes will include:

  • Rapid adoption of digitization in drug discovery and clinical trials.
  • Precision medicine’s impact on drug development.
  • The evolution and implications of new models in clinical trial recruitment.
  • The changing partnership ecosystem – biopharma, technology platforms, investors, regulatory and patients.
Harry Glorikian | Speaking at AI Applications Summit | Biopharma

Harry Glorikian

General Partner New Ventures Funds Author: MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market
9:00 AM - 9:40 AM

Executive Viewpoints: Will AI Be Innovation or Renovation for Biopharma?

How will big pharma approach innovation? Is today’s biotech model, really yesterday’s? These questions are the foundation of this lively discussion and debate. What is the perceived impact of AI on current R&D business models? This session will examine what’s really going on. What do companies have to change to be an AI first or an AI embedded organization? Is there a place where renovation is appropriate, and what does true innovation really look like?


Milind Kamkolkar | Speaking at AI Applications Summit | Biopharma

Dr. Milind Kamkolkar

Chief Data Officer Cellarity - a Flagship Pioneering Company


Birgit Schoeberl, Ph.D.

Global Head of Modeling and Simulation, PK Sciences Novartis Institutes for BioMedical Research (NIBR)
Krishna Cheriath

Krishna Cheriath

Chief Data Officer Bristol-Myers Squibb
Vipin Gopal

Vipin Gopal Ph.D.

Chief Data and Analytics Officer Eli Lilly and Company

Disrupting the Status Quo With Visionary Models For Collaboration

9:40 AM - 9:55 AM

How to Find the Right External Partners to Leverage New Technologies

Innovative technologies in drug development are impacting the pharmaceutical and biotech industries. This session will discuss how to engage outside partners so you don’t have to go it alone when adopting new technology. It will also explore the hype vs. reality surrounding cutting edge developments and their impact on business models. Dave Meyers will discuss global market trends and opportunities surrounding new technologies such as artificial intelligence and how to select and go to market with partners to solve business problems.

Dave Meyers

National Director US Life Sciences Industry Microsoft
9:55 AM - 10:10 AM

Internal Collaboration: Moving Toward the Value of End-to-End Machine Learning for Pipeline Optimization

The results of a landmark study published in Nature Biotechnology in September, 2019 will be presented at the Summit. In the study, Insilico Medicine showed that they designed a drug candidate from scratch in 21 days and validated it in 25 days. This is the first time that GAN-RL technology, which is a combination of Generative Adversarial Networks and Reinforcement Learning, was used to generate novel small molecules for a protein target that were validated in vitro and in vivo. Since the molecules are generated with the specific conditions and objectives in mind including safety, it is likely that these molecules will have better chances of passing through clinical trials. Don’t miss this opportunity to hear first-hand how the transformative potential of AI has been validated in practice.

Dr. Qingsong Zhu Ph.D.

COO Insilico Medicine, Inc
10:10 AM - 10:40 AM

Networking, Refreshments & Expert One-to-One Meetings

Drug Discovery

10:40 AM - 11:35 AM

R&D Use Cases

Drug Discovery is a long process that AI technologies and tools are beginning to help shorten.  The speakers in this two-part R&D Use Case session will present information on current projects where they are applying AI.  They will cover the inputs and outcomes, as well as share insights from applying AI  to their discovery projects


Alan Louie | Speaking at AI Applications Summit | Biopharma

Alan S. Louie, PhD

Research Director, Life Sciences IDC Health Insights


Robert Abel

Robert Abel, Ph.D.

Senior Vice President, Sciences Schrödinger
Ron Alfa | Speaker | AI Applications Summit

Ron Alfa, MD, Ph.D

Senior Vice President, Translational Discovery Recursion Pharmaceuticals Co-founder, Board of Directors, Executive Committee, The Alliance for Artificial Intelligence in Healthcare (AAIH)

Martin Akerman

Co-founder and CTO Envisagenics
  • Envisagenics’ platform, SpliceCore, uses AI to discover druggable splicing errors: Use cases in identifying and validating novel targets for triple-negative breast cancer.

Kate Hilyard, Ph.D.

Chief Operating Officer Healx

The use of AI in accelerating new rare disease drugs towards the clinic
This use case will discuss how AI enabled us to get from disease selection to clinical candidate selection for fragile X syndrome in 24 months.

• How AI and ML predict viable treatment options

• The importance of partnership and patient insight – FRAXA Research Foundation example

• Preclinical proof of concept for fragile X syndrome

• Progression to clinical trials

Rishi R. Gupta, Ph.D.

Principal Research Scientist, Data Science & Informatics AbbVie

Boosting Drug Discovery with Machine Learning

Applying recent advances made in Artificial Intelligence (AI) and Machine Learning (ML) methods to advance decision making in many industries has become an extremely important area of applied research. Progress in this regard will come from combining an understanding of the current and potential decision making processes specific to the industry of interest along with new and careful approaches to data capture that support training of the data using an appropriate method of choice. How machine learning tools can increase the efficiency and expediency of this decision by helping various research groups within a Pharmaceutical organization will be presented along with case studies highlighting the application of ML methods in discovery and pharmacovigilance.

11:35 AM - 12:05 PM

Employing AI to find the Translational Piece for Making Drugs Effective, Validated and Useful in Humans

AI tools are making drug discovery more efficient, but the real win from AI is about achieving a higher rate of translation and success rates from biology to pre-clinical and from pre-clinical to clinical programs. The use cases in this session will cover the use of AI tools in prioritizing drug candidates that will be most effective, validated and useful.

Brandon Allgood

Brandon Allgood

CTO and Co-Founder Numerate Co-Founder & Vice Chair, The Alliance for Artificial Intelligence in Healthcare (AAIH)

Case Studies: Improving Translation using AI from Biology to Pre-Clinical, and from Pre-Clinical to Clinical Programs


Heather A. Arnett, Ph.D.

Vice President, Research NuMedii

Using single cell RNAseq and AI to identify therapeutic targets in fibrosis

Jörg Bentzien

Jörg Bentzien

Research Fellow, Discovery Alkermes, Inc.

This case study will cover the automation of the Design-Make-Test-Analyze cycle in early drug discovery. The focus will be on how automation can be used to make better decisions and on the concept of automatically self-updating predictive models.

12:05 PM - 1:05 PM

Networking Lunch & Expert One-to-One Meetings

AI for Clinical Development

1:05 PM - 1:30 PM

Getting to the Proof of Innovation: AI Use Cases in Drug Development and Clinical Trials

Using Deep Learning to Improve Drug Development Success Outcomes

This session will look at how AI technology such as Deep Learning is being applied to the challenge of drug failure, both in discovery and in clinical trials. One of the primary drivers of R&D expense is the high number of failures that occur during the development of a therapeutic. Many pharmaceutical companies are now looking at AI solutions to better predict which assets will succeed in trials, and to design compounds have been optimized for success. Some specific examples:

  • Using clinical trial outcomes to improve estimates of success.
  • Currently approximately 50% of trials fail due to ADME/Tox issues – examples of how Pfizer is using DL to help change this.
  • How is medicinal chemistry and design changing with AI?
  • Using AI earlier in the discovery cycle to select targets and indications for investment.
Michael G Frank | Speaker | AI Applications Summit

Michael G. Frank

Director, World Wide R&D Strategy Pfizer

Data-Driven Approaches to Clinical Trial Selections

Dr. Mark F. Ciaccio

Senior A.I. Data Scientist AbbVie
1:30 PM - 2:00 PM

Realizing the Potential of Virtual and Hybrid Clinical Trials

The need to increase the speed of patient recruitment, improve retention, and enhance data quality – all while lowering costs, has led to the current interest in virtual and hybrid clinical trials. The question is, how do you know when a virtual or hybrid study makes sense? This session will focus on the critical differences between traditional and virtual or hybrid trials that need to be considered.

  • What therapeutic areas are most effective using virtual and hybrid trials?
  • The importance of protocol design and a distribution and tracking plan for medication.
  • Understanding How Digital Therapeutics Will Change the Clinical Trial Paradigm.
  • What steps need to be taken to ensure the safety of patients?
  • If the home is the new trial site, how is that different? What do you need to do differently from the start of the process through the end of the trial?
  • Understanding How Digital Therapeutics Will Change the Clinical Trial Paradigm.


Nitin Naik | Speaker | AI Applications Summit

Nitin Naik

Vice President-Global Life Sciences, Transformational Health Frost & Sullivan


Dr. Michelle Longmire, CEO & Co-Founder, Medable

Dr. Michelle Longmire

CEO & Co-Founder Medable
Mohammed Ali | Speaker | AI Applications Summit

Mohammed Ali

Global Head Digital Trials- Global Clinical Operations Boehringer Ingelheim Pharmaceuticals, Inc.
2:00 PM - 2:30 PM

Using Robotic Process Automation (RPA) to Optimize Human Capital & Improve Efficiency and Compliance


Tom Davenport

Distinguished Professor Babson College; Research Fellow, MIT Initiative on the Digital Economy


Catherine Calarco

Catherine Calarco

Senior Director, Industry Strategy and Marketing for Life Sciences Automation Anywhere
2:30 PM - 3:00 PM

Afternoon Refreshments & Expert One-to-One Meetings

3:00 PM - 3:50 PM

Deep Dive Concurrent Sessions

Clinical Development

Mohammed Ali | Speaker | AI Applications Summit

Mohammed Ali

Global Head Digital Trials- Global Clinical Operations Boehringer Ingelheim Pharmaceuticals, Inc.

Data Democratization & Interoperability

Ed Bowen

Vice President, AI & Machine Learning, Medicinal Science and Technology (MST) GSK


Brian S. Martin, Head of AI R&D Information Research, AbbVie

Brian S. Martin

Head of AI R&D Information Research AbbVie
3:55 PM - 4:25 PM

An AI Powered Project: Human Genetics & Drug Discovery

This session will discuss various projects and their potential impact on the industry when the big data derived from the human genome is married with breakthroughs from artificial intelligence.


Gunaretnam Rajagopal | Speaker | AI Applications Summit

Dr. Gunaretnam (Guna) Rajagopal

VP Global Head – Computational Sciences, Discovery Sciences Janssen Research & Development, A Johnson & Johnson Company


John Reynders

Vice President, Data Science, Genomics, and Bioinformatics Alexion Pharmaceuticals, Inc.
  • Answering the question “how many rare diseases are there?” and navigating the rare-disease landscape with data sciences
  • If Amazon can recommend a book we might like, can we use AI to help a doctor ask the next right question to enable a rare-disease diagnosis?
  • How to set a world record in rare-disease diagnosis – hint: genomics + AI
Panna Sharma

Panna Sharma

CEO Lantern Pharma
  • How Lantern Pharma is revolutionizing the drug development process by implementing its RADR platform, which leverages AI, ML and genomics, to increase clinical trial success rates as well as reduce timelines and costs.
  • Use Cases for drugs LP100, LP184 and LP300
4:25 PM - 5:00 PM

Innovation Spotlight Changemaker Presentations

The Innovation Spotlight Presentation program features six changemaker speakers along with moderator Travis McCready, President & CEO of Massachusetts Life Sciences Center. Each speaker presents a concise and fast-paced 5-minute presentation that will introduce you to an innovative way of solving a problem, a new technology or tool, or a transformative approach to solving common issues facing biopharma companies today. Immediately following the spotlight presentations, attendees can meet with these innovative companies in a relaxed atmosphere during the evening reception.


Travis McCready | Speaker | AI Applications Summit

Travis A. McCready

President & CEO Massachusetts Life Sciences Center

Changemaker Presenters

Ijah Mondesire-Crump, MD

Ijah Mondesire-Crump, MD

Director of Clinical Research nQ Medical, Inc.
  • Organizations must recognize barriers to adoption of digital health. Proprietary devices and task-based apps are inversely proportional to patient adoption.
  • Target “people” and not just patients.
  • Digital health products must be built on tomorrow’s healthcare system, not today’s.


kyle martin

Kyle Martin Flickinger

Vice President Bio Pharmaceutical Solution Strategy Deep Lens
  • Speed to Hope – What does confirmation of diagnosis in precision oncology really imply?
  • The use of digital pathology case management workflow and AI to support clinical research as a care option:
      – What is the need? What are the solutions? Where is Digital pathology heading?


Tim Gardner

Tim Gardner, Ph.D.

Founder/CEO Riffyn

Lab data to machine learning in 30 seconds

  • Lab challenge: data heterogeneity, silos, constant change in R&D
  • Data challenge: systems lack structure, flexibility, accessibility
  • Solution: evolvable “scientific blueprints”: bridge silos with clean & connected data
Nora Khaldi

Nora Khaldi, Ph.D.

Founder & CSO Nuritas, Ltd.
Matthew A. Michela, President and CEO, Life Image

Matthew A. Michela

President and CEO Life Image
David Wild, Ph.D | Speaker | AI Applications Summit

David Wild, Ph.D.

Founder & President Data2Discovery Inc
  • Data2Discovery is applying AI in drug discovery and decreasing the process from 6 years to 6 weeks!
  • By using target identification methods and a disease-driven approach to find new therapies, the cost it takes to bring a drug to market is significantly reduced.
  • David will discuss Use Case examples which address: 1) the business problem of finding new leads as quickly as possible for an ROI, and 2) how the importance of understanding the disease and the intricate biological
    relationships in the data is crucial.

5:00 PM - 6:00 PM

Evening Reception


8:55 AM - 9:00 AM

Chairman's Remarks

Brian S. Martin, Head of AI R&D Information Research, AbbVie

Brian S. Martin

Head of AI R&D Information Research AbbVie

Real-World Evidence

9:00 AM - 9:25 AM

Overcoming Barriers to RWE Adoption and Realizing Value


Janak Joshi, Senior Vice President, Chief of Technology and Head of Strategy, Life Image

Janak Joshi

Senior Vice President, Chief of Technology and Head of Strategy Life Image


Charles Makin | Speaker | AI Applications Summit

Charles Makin, BSPharm, MS, MBA, MM

Global Head, Real World Evidence Strategy Biogen

Bolan Linghu, Ph.D.

Associate Director, Oncology Bioinformatics AstraZeneca
9:25 AM - 9:50 AM

Innovate Practically: Finding the Intersections Between AI and RWE to Better Treat Patients

This session will cover how biopharma companies are using real world data combined with AI to enhance business value and impact. While still in the nascent stages, the practice of real-world data analytics is moving beyond primarily post-approval applications and is being institutionalized across organizations. Themes to be discussed include:

  • Overcoming cultural resistance to using real world data.
  • Adopting and effectively utilizing real-world evidence to develop the innovative medicines of the future.
  • Collaborating with strategic partners to identify specific use cases that advance your efforts and deliver beneficial therapies faster to patients.


Jeff Elton

CEO Concerto HealthAI


Chris Boone Ph.D | Speaker | AI Applications Summit

Christopher Boone, Ph.D, FACHE

Vice President, Global Medical Epidemiology & Big Data Analysis Lead Pfizer

Vitaly Doban

Executive Director, Head of RWE Advanced and Applied Analytics Novartis Oncology
9:50 AM - 10:15 AM

Update on FDA's Real-World Evidence Program

This session will cover the main elements of the framework for FDA’s real-world evidence program and will describe ongoing demonstration projects and collaborations. The emerging and evolving role of technological innovations in facilitating the use of real-world data will be discussed and highlighted. Examples of activities focused on the utilization of AI to support the development of therapeutics will be provided.

M. Khair ElZarrad Ph.D., MPH, Deputy Director, Office of Medical Policy

M. Khair ElZarrad Ph.D., MPH

Deputy Director, Office of Medical Policy Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA)

Data Management

10:15 AM - 10:40 AM

Data Diversity and Access: Impacting Patients in Meaningful Ways and Avoiding Data Biases

Effective data management is the foundation of successful AI/ML use. This session will cover critical components of data management that you have to get right in order to use AI technology in meaningful ways.

  • How to apply FAIR Data Principles to scientific data management.
  • Challenges for establishing a data-driven drug discovery landscape.
  • Policy decisions that can help or hinder R&D.
  • How can AI be used to help make policy decisions impacting quality of data, standardization of data and access to data?
  • How can ML help avoid data biases and remove unintended bias from your data?
Bhanu Bahl

Bhanu Bahl, Ph.D.

Head of Discovery Informatics, Data Sciences H3 Biomedicine

Gabriela Lavezzari

Senior Director, US R&D Policy & Scientific Affairs, R&D Strategy, Portfolio & Operations GSK
10:40 AM - 11:10 AM

Morning Refreshments

11:10 AM - 11:35 AM

Data Organization and Communication: Unlocking the Value of Insights

This session features two case study presentations that will address the importance of data organization across an organization to unlock the value of the data being collected.

  • Why one-size-fits-all systems don’t work (at least right now).
  • Janssen’s “ecosystem of platforms” approach to taking existing systems for different purposes and integrating them for better data access.
  • Methods for capturing data sets to do analysis across the company instead of in silos.
  • A view into current Janssen projects.

Dr. Bhaskar Dutta

Head of Technology and Analytics: Oncology Regulatory Science & Strategy AstraZeneca
Joseph Lehar | Speaker | AI Applications Summit

Joseph Lehar

VP of Data Science, Oncology The Janssen Pharmaceutical Companies of Johnson & Johnson
11:35 AM - 12:00 PM

Confessions of a Data Scientist in Pharma: Working in an Analog Industry in a Digital World

In this session Alex will talk about his experience managing data science across all of Vertex and Alex and Lixia will lead a discussion about the triumphs and tribulations of being a data scientist in pharma. Themes to be covered include:

  • Steps to becoming a data-driven company across all functional areas.
  • How do you institutionalize operational effectiveness?
  • What are the key elements to building a data science culture with alignment across the organization?
  • How can you compete for talent?
  • How can you manage the hype around savings and success?
  • Managing through the Tower of Babel of data.
Lixia Wang

Lixia Wang

Vice President, Biostatistics and Data Management Intercept Pharmaceuticals
Alex Aronov

Alex Aronov Ph.D., MBA

Senior Director, Data Strategy & Solutions Vertex Pharmaceuticals
12:00 PM - 12:40 PM

Open Discussion: New Collaborative Models to Impact Patients in More Meaningful Ways

Several industry pioneers will lead an audience-wide discussion on the collaborative models in use that are impacting patients now. This is your unique opportunity to gain an understanding of how industry peers are innovating via collaborative models with each other, technology partners and academia. This is also a great opportunity to expand your network and possibly find your next partner.


Jennifer K. Pai | Speaker | AI Applications Summit

Jennifer K. Pai, ScD

Director, Data Sciences, Strategy & Platforms Merck & Co., Inc.


Niven Narain | Speaker | AI Applications Summit

Niven R. Narain Ph.D.

Co-Founder, President & CEO BERG

Bolan Linghu, Ph.D.

Associate Director, Oncology Bioinformatics AstraZeneca
M. Khair ElZarrad Ph.D., MPH, Deputy Director, Office of Medical Policy

M. Khair ElZarrad Ph.D., MPH

Deputy Director, Office of Medical Policy Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA)
12:40 PM - 12:45 PM

Chair's Closing Remarks

Brian S. Martin, Head of AI R&D Information Research, AbbVie

Brian S. Martin

Head of AI R&D Information Research AbbVie